bioGenous Biotechnology
PrivateLast Round
Series A
Extension
Dec 31, 2024
Total Funding Raised
$14.7M
Company Overview
bioGenous Biotechnology operates in Healthcare & Life Sciences and is based in Suzhou. Its latest recorded funding round was a Series A Extension round in December 2024.
bioGenous Biotechnology is a biotechnology company that specializes in organoid construction, drug testing, and multi-omics analysis, providing standardized organoid products and integrated technical services for the biopharmaceutical industry.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Biotech Equipment, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Hardware Sales, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
bioGenous Biotechnology Comparables
Compare bioGenous Biotechnology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| K2 Oncology | 87% | |
| AimingMed | 87% | |
| Accurate International Biotechnology | 84% |
For institutional investors. Book with your work email.
bioGenous Biotechnology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Dec 31, 2024 | ||||
| Series A | Jan 5, 2023 | ||||
| Early Funding | Oct 14, 2022 | ||||
| Angel | Aug 10, 2021 |
For institutional investors. Book with your work email.
bioGenous Biotechnology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SDIC Fund Management | Series A |
| Marathon Venture Partners | Series A, Early Funding |
| 源创多盈投资 | Early Funding, Angel |
| CICC Capital | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 31, 2024
Led by CICC Capital
- Jan 5, 2023
$15M round led by SDIC Fund Management.
For institutional investors. Book with your work email.
bioGenous Biotechnology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about bioGenous Biotechnology's valuation, stock price, and market status.
Is bioGenous Biotechnology a public or private company?
bioGenous Biotechnology is a private company.
What is the current stock price of bioGenous Biotechnology?
bioGenous Biotechnology is a private company, so its shares have no public market price. Caplight tracks bioGenous Biotechnology's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is bioGenous Biotechnology worth (valuation)?
Valuation information for bioGenous Biotechnology is not publicly available.
Can I buy bioGenous Biotechnology stock?
bioGenous Biotechnology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was bioGenous Biotechnology's last funding round?
bioGenous Biotechnology's most recent funding round was Series A Extension on December 31, 2024.
Who are the main investors in bioGenous Biotechnology?
Key investors in bioGenous Biotechnology include SDIC Fund Management, CICC Capital.
Will bioGenous Biotechnology IPO soon?
No public IPO plans have been announced for bioGenous Biotechnology.
How can I track bioGenous Biotechnology secondary market activity?
Caplight tracks bids, offers, and trades in bioGenous Biotechnology's shares on secondary markets.